The role of angiocidin in sarcomas

Cancer

Volumn 115, Issue 22, 2009, Pages 5251-5262

  Liebig, Catherine ^a   Wilks, Jonathan A ^a   Feig, Barry W ^b   Wang, Thomas N ^c   Wilson, Mariya ^c   Herdman, Ann V ^c   Albo, Daniel ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Angiocidin; Angiocidin inhibitory peptide; CSVTCG; Extraskeletal osteosarcoma; Peptide therapy; Sarcomas; Thrombospondin 1

Indexed keywords

CARRIER PROTEIN; GELATINASE; PROTEIN ANGIOCIDIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; UPREGULATION;

ANTIGENS, CD36; CARRIER PROTEINS; GELATINASES; HUMANS; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; SARCOMA; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 70449369322     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24568     Document Type: Article

References (42)

1. Perez-Mancera PA, Sanchez-Garcia I. Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model. Semin Cancer Biol. 2005;15:206-214. (Pubitemid 40501735)
2. Schlieman M, Smith R, Kraybill WG. Adjuvant therapy for extremity sarcomas. Curr Treat Options Oncol. 2006;7:456-463.
3. Seynaeve C, Verweij J. High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol. 1999;26:119-133.
4. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238-1247. (Pubitemid 32202526)
5. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer. 1995;72:469-475.
6. Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol. 2006;18:354-359.
7. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779-1802. (Pubitemid 46038527)
8. Yang X, Rothman VL, L'Heureux DZ, Tuszynski G. Reduction of angiocidin expression in human umbilical vein endothelial cells via siRNA silencing inhibits angiogenesis. Exp Mol Pathol. 2006;81:108-114. (Pubitemid 44715794)
9. Zhou J, Rothman VL, Sargiannidou I, et al. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J Cell Biochem. 2004;92:125-146.
10. Sabherwal Y, Rothman VL, Dimitrov S, et al. Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp Cell Res. 2006;312:2443-2453. (Pubitemid 44036798)
11. Sabherwal Y, Rothman VL, Poon RT, Tuszynski GP. Clinical significance of serum angiocidin levels in hepatocellular carcinoma. Cancer Lett. 2007;251:28-35. (Pubitemid 46589763)
12. Roth JJ, Buckmire MA, Rolandelli RH, Granick MS, Tuszynski GP. Localization of thrombospondin-1 and its cysteine-serine-valine-threonine- cysteine-glycine receptor in colonic anastomotic healing tissue. Histol Histopathol. 1998;13:967-971.
13. Roth JJ, Sung JJ, Granick MS, et al. Thrombospondin 1 and its specific cysteine-serine-valine-threonine-cysteine-clycine receptor in fetal wounds. Ann Plast Surg. 1999;42:553-563.
14. Poon RT, Chung KK, Cheung ST, et al. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res. 2004;10(12 pt 1):4150-4157. (Pubitemid 38812495)
15. Tuszynski GP, Rothman VL, Papale M, Hamilton BK, Eyal J. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain. J Cell Biol. 1993;120:513-521. (Pubitemid 23040089)
16. Albo D, Shinohara T, Tuszynski GP. Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res. 2002;108:51-60. (Pubitemid 35373815)
17. Tuszynski GP, Rothman VL, Deutch AH, Hamilton BK, Eyal J. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins. J Cell Biol. 1992;116:209-217.
18. Tuszynski GP, Srivastava S, Switalska HI, Holt JC, Cierniewski CS, Niewiarowski S. The interaction of human platelet thrombospondin with fibrinogen. Thrombospondin purification and specificity of interaction. J Biol Chem. 1985;260:12240-12245. (Pubitemid 16228396)
19. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem. 1994;269:26775-26782. (Pubitemid 24332871)
20. Sargiannidou I, Qiu C, Tuszynski GP. Mechanisms of thrombospondin-1- mediated metastasis and angiogenesis. Semin Thromb Hemost. 2004;30:127-136.
21. Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J CellBiol. 1994;124:183-193.
22. Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res. 1998;4:230-241.
23. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987;47:3239-3245. (Pubitemid 17082655)
24. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
25. Albo D, Berger DH, Tuszynski GP. The effect of thrombospondin- 1 and TGF-beta 1 on pancreatic cancer cell invasion. J Surg Res. 1998;76:86-90. (Pubitemid 28363860)
26. Albo D, Berger DH, Vogel J, Tuszynski GP. Thrombospondin- 1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer. J Gastrointest Surg. 1999;3:411-417.
27. Albo D, Rothman VL, Roberts DD, Tuszynski GP. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer. 2000;83:298-306. (Pubitemid 30453567)
28. Castle V, Varani J, Fligiel S, Prochownik EV, Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest. 1991;87:1883-1888.
29. Qian X, Rothman VL, Nicosia RF, Tuszynski GP. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res. 2001;7:251-259. (Pubitemid 34174690)
30. Tuszynski GP, Nicosia RF. The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays. 1996;18:71-76. (Pubitemid 3023309)
31. Tuszynski GP, Nicosia RF. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycinespecific receptor in human breast carcinoma. Lab Invest. 1994;70:228-233. (Pubitemid 24090105)
32. Wakiyama T, Shinohara T, Shirakusa T, John AS, Tuszynski GP. The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine- cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. Histol Histopathol. 2001;16:345-351. (Pubitemid 32297631)
33. Tobita K, Kijima H, Dowaki S, et al. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol. 2002;21:1189-1195.
34. Wang TN, Qian X, Granick MS, et al. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res. 1996;63:39-43. (Pubitemid 26197174)
35. Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res. 1997;235:403-412. (Pubitemid 27398399)
36. Bloomston M, Zervos EE, Rosemurgy AS II. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol. 2002;9:668-674. (Pubitemid 34857984)
37. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7:14-23. (Pubitemid 32591662)
38. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994;54:6504-6511.
39. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol. 1995;130:503-506.
40. Roth JJ, Albo D, Rothman VL, et al. Thrombospondin-1 and its CSVTCG-specific receptor in wound healing and cancer. Ann Plast Surg. 1998;40:494-501. (Pubitemid 28215521)
41. Arnoletti JP, Albo D, Jhala N, et al. Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am J Surg. 1994;168:433-436. (Pubitemid 24345691)
42. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49:187-198.